Bilaketaren emaitzak - Maura Watmuff

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) nork Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

Testu osoa